KR20100131471A - 리포솜 보톨리눔 독소를 이용한 방광기능장애의 치료 - Google Patents

리포솜 보톨리눔 독소를 이용한 방광기능장애의 치료 Download PDF

Info

Publication number
KR20100131471A
KR20100131471A KR1020107022175A KR20107022175A KR20100131471A KR 20100131471 A KR20100131471 A KR 20100131471A KR 1020107022175 A KR1020107022175 A KR 1020107022175A KR 20107022175 A KR20107022175 A KR 20107022175A KR 20100131471 A KR20100131471 A KR 20100131471A
Authority
KR
South Korea
Prior art keywords
bladder
bont
liposomes
liposome
bonts
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107022175A
Other languages
English (en)
Korean (ko)
Inventor
마이클 비. 첸셀러
조나단 에이치. 카우프만
Original Assignee
리펠라 파마슈티칼즈, 인코포레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리펠라 파마슈티칼즈, 인코포레이티드. filed Critical 리펠라 파마슈티칼즈, 인코포레이티드.
Publication of KR20100131471A publication Critical patent/KR20100131471A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107022175A 2008-04-04 2009-04-03 리포솜 보톨리눔 독소를 이용한 방광기능장애의 치료 Ceased KR20100131471A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4253608P 2008-04-04 2008-04-04
US61/042,536 2008-04-04
US11026608P 2008-10-31 2008-10-31
US61/110,266 2008-10-31

Publications (1)

Publication Number Publication Date
KR20100131471A true KR20100131471A (ko) 2010-12-15

Family

ID=41319235

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107022175A Ceased KR20100131471A (ko) 2008-04-04 2009-04-03 리포솜 보톨리눔 독소를 이용한 방광기능장애의 치료

Country Status (10)

Country Link
US (1) US20120093920A1 (cg-RX-API-DMAC7.html)
EP (2) EP2599476A1 (cg-RX-API-DMAC7.html)
JP (2) JP5538359B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100131471A (cg-RX-API-DMAC7.html)
CN (1) CN102065841A (cg-RX-API-DMAC7.html)
AU (1) AU2009246834B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0911098A2 (cg-RX-API-DMAC7.html)
CA (1) CA2720523C (cg-RX-API-DMAC7.html)
MX (1) MX2010010635A (cg-RX-API-DMAC7.html)
WO (1) WO2009139984A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220030518A (ko) * 2020-09-03 2022-03-11 충남대학교병원 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
BR112015004110A2 (pt) 2012-08-31 2017-07-04 Taris Biomedical Llc sistemas e métodos de distribuição de drogas para tratamento de próstata
SI2890384T1 (sl) 2012-08-31 2022-02-28 Taris Biomedical Llc Sistemi za dostavo zdravila in postopki za zdravljenje raka sečnega mehurja, ki obsegajo oksaliplatin
EP3060197B1 (en) 2013-10-22 2023-06-07 Lipella Pharmaceuticals Inc. Delivery of agents using metastable liposomes
US20150250717A1 (en) 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
US20160045623A1 (en) 2015-04-03 2016-02-18 Lipella Pharmaceuticals, Inc. Systems and Methods to Image Intercellular and Intercompartmental Defects with Magnetic Resonance Imaging (MRI)
US10857173B2 (en) 2017-07-25 2020-12-08 Taris Biomedical Llc Methods of treating tumor metastasis
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
JOP20200124A1 (ar) 2017-11-08 2020-05-20 Taris Biomedical Llc طُرق لعلاج سرطان المثانة باستخدام جيمسيتابين وعلاج مدوامة لذلك
TWI760996B (zh) * 2020-12-25 2022-04-11 姜秉均 含有疏水性物質的奈米組成物及其製備方法與用途
CN117598911A (zh) * 2022-12-09 2024-02-27 崔蕾 一种肉毒素脂质体透明质酸凝胶的制备方法
CN117883383A (zh) * 2023-12-26 2024-04-16 中国康复研究中心 一种作为A型肉毒素载体的TiO2纳米粒子及制备方法
US12272439B1 (en) 2024-05-06 2025-04-08 Immunitybio, Inc. Distributed ledger for medicament administration tracking

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3693209B2 (ja) * 1996-04-11 2005-09-07 三菱化学株式会社 閉鎖小胞の製造方法
WO2003015698A2 (en) * 2001-08-13 2003-02-27 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
US20030224020A1 (en) * 2002-05-31 2003-12-04 Zabudkin Alexander F. Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use
US20040067235A1 (en) 2002-07-29 2004-04-08 Rajiv Doshi Methods for the use of neurotoxin in the treatment of urologic disorders
JP2006508126A (ja) * 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
WO2007044748A2 (en) 2005-10-11 2007-04-19 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220030518A (ko) * 2020-09-03 2022-03-11 충남대학교병원 초음파유도 마이크로버블을 포함하는 배뇨장애 치료제 조성물

Also Published As

Publication number Publication date
US20120093920A1 (en) 2012-04-19
WO2009139984A2 (en) 2009-11-19
EP2273976A2 (en) 2011-01-19
JP5538359B2 (ja) 2014-07-02
JP2011516497A (ja) 2011-05-26
EP2599476A1 (en) 2013-06-05
JP2014062125A (ja) 2014-04-10
MX2010010635A (es) 2010-12-17
AU2009246834B2 (en) 2012-12-06
CN102065841A (zh) 2011-05-18
WO2009139984A3 (en) 2010-03-04
CA2720523A1 (en) 2009-11-19
BRPI0911098A2 (pt) 2015-10-06
CA2720523C (en) 2013-12-17
AU2009246834A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
AU2009246834B2 (en) Treatment of bladder dysfunction using liposomal botulinum toxin
Liu et al. Multifunctional hydrogel eye drops for synergistic treatment of ocular inflammatory disease
Fraser et al. Intravesical liposome administration—a novel treatment for hyperactive bladder in the rat
Chancellor et al. Treatment of interstitial cystitis
Jiang et al. Controlled release of anti-VEGF by redox-responsive polydopamine nanoparticles
JP2003519666A (ja) 膵臓障害の処置方法
KR101464208B1 (ko) 당뇨성 신경병증에서 말초 신경의 형태기능의 복원을 위한 상피 성장인자의 용도
Lv et al. Chitosan as a promising materials for the construction of nanocarriers for diabetic retinopathy: an updated review
CN103813802A (zh) 用于治疗与性活动相关的失禁的方法
US20120301540A1 (en) Method of treatment for bladder dysfunction
Zhang et al. An injectable thermosensitive hyaluronic acid/pluronic F-127 hydrogel for deep penetration and combination therapy of frozen shoulder
Zhang et al. Inhalation of taraxasterol loaded mixed micelles for the treatment of idiopathic pulmonary fibrosis
Lin et al. Nanoparticle-mediated intravesical delivery of conditioned medium derived from mesenchymal stem cells for interstitial cystitis/bladder pain syndrome treatment
Fraser et al. The future of bladder control—intravesical drug delivery, a pinch of pepper, and gene therapy
de Sèze et al. Intravesical glucidic capsaicin versus glucidic solvent in neurogenic detrusor overactivity: a double blind controlled randomized study
Gupta et al. Understanding the routes of administration
IT202300003891A1 (it) Utilizzo di miriocina come adiuvante nella chirurgia del glaucoma
US20160331683A1 (en) Water-in-oil type emulsion for treating a disease of the eye
CN115942945A (zh) 含源自副干酪乳杆菌的细胞外囊泡的预防或治疗眼病的组合物
Liu et al. Nano-BTA: A new strategy for intravesical delivery of botulinum toxin A
Hung et al. Role of liposome in treatment of overactive bladder and interstitial cystitis
US8283323B2 (en) Withanolide compounds as inhibitors of fibrosis and identification of molecular targets for anti-fibrotic drug development
CN105342984A (zh) 一种用于治疗急性胰腺炎的可注射温敏凝胶制剂
KR20230042974A (ko) mTOR 활성화제를 포함하는 안질환 치료용 조성물 및 이의 용도
US20150045296A1 (en) Method for treating diabetic retinopathy

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101004

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140403

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150903

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151106

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150903

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I